List of Excipients in Branded Drug CARTIA

Generic Drugs Containing CARTIA

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	diltiazem hydrochloride	50090-3051	ACETYLTRIBUTYL CITRATE
A-S Medication Solutions	diltiazem hydrochloride	50090-3051	AMMONIO METHACRYLATE COPOLYMER TYPE B
A-S Medication Solutions	diltiazem hydrochloride	50090-3051	D&C RED NO. 28
A-S Medication Solutions	diltiazem hydrochloride	50090-3051	D&C YELLOW NO. 10
A-S Medication Solutions	diltiazem hydrochloride	50090-3051	ETHYLCELLULOSE

What are the Most Frequently-Used Excipients in CARTIA?

# Of NDCs	Excipient
5	ACETYLTRIBUTYL CITRATE
5	AMMONIO METHACRYLATE COPOLYMER TYPE B
5	D&C RED NO. 28
5	D&C YELLOW NO. 10
5	ETHYLCELLULOSE

Excipient Strategy and Commercial Opportunities for CARTIA

Last updated: February 26, 2026

What is the excipient strategy for CARTIA?

CARTIA contains the active pharmaceutical ingredient (API) nicardipine, a dihydropyridine calcium channel blocker used primarily for hypertension and angina. Its formulation relies on excipients that ensure stability, bioavailability, and patient compliance.

• Core excipients include:

  • Binders: Microcrystalline cellulose or lactose, facilitating tablet cohesion.
  • Disintegrants: Croscarmellose sodium or sodium starch glycolate, promoting tablet breakup in the gastrointestinal tract.
  • Fillers: Dicalcium phosphate or lactose, providing bulk.
  • Lubricants: Magnesium stearate, reducing manufacturing friction.
  • Coatings: Hydroxypropyl methylcellulose (HPMC) or ethylcellulose for controlled release or stability.

• Formulation considerations:

  • Compatibility with the API to prevent degradation.
  • Ensuring uniformity in dose and stability over shelf life.
  • Optimizing for immediate or sustained release, depending on the marketed formulation.

How does CARTIA's excipient strategy compare with industry standards?

Aspect	Industry Standard	CARTIA-specific approach
Dissolution control	Use of standard disintegrants	Use of specialized disintegrants to optimize bioavailability
Stability	Common excipients like HPMC or lactose	Careful selection to mitigate API degradation, especially in API's sensitivity to moisture and light
Release profile	Immediate release	Depending on the formulation, potential for controlled-release variants

Manufacturers may modify excipients to meet regional regulatory standards, patient preferences, or to develop value-added formulations.

What are the commercial opportunities tied to excipients for CARTIA?

• Formulation differentiation:

  • Developing controlled-release versions to improve compliance.
  • Introducing formulations with reduced excipient loads for sensitive populations.

• Manufacturing efficiencies:

  • Using excipients that enable faster processing or reduce costs.
  • Sourcing excipients from reliable suppliers to minimize supply chain disruptions.

• Market expansion:

  • Creating pediatric or geriatric formulations with excipients suited for those populations.
  • Developing combination therapies with excipients compatible across multiple APIs.

• Regulatory advantages:

  • Employing excipients with well-characterized safety profiles could simplify approval pathways.
  • Using excipients approved in multiple jurisdictions streamlines global registration.

• Intellectual property:

  • Formulating novel excipient combinations or coatings could generate patentable formulations.
  • Securing patents on unique excipient interactions enhances market exclusivity.

What challenges and considerations exist for excipient strategies with CARTIA?

• Regulatory compliance:
  Ensuring excipients meet health authority standards (FDA, EMA) and are listed in pharmacopeias.

• API stability:
  Protecting nicardipine’s stability, particularly against moisture and light, with suitable excipients.

• Patient safety:
  Selecting non-allergenic, biocompatible excipients, especially for extended-release products.

• Supply chain:
  Securing access to high-quality excipients at competitive prices amid global shortages.

• Cost considerations:
  Balancing excipient quality and formulation complexity against pricing pressures.

Summary of key formulations and excipient considerations

Formulation Type	Key Excipients	Commercial Opportunities
Immediate Release	Microcrystalline cellulose, croscarmellose sodium, magnesium stearate	Cost-effective, large-scale production, broad market access
Controlled Release	Ethylcellulose, HPMC, ethylcellulose coatings	Higher pricing, radiation of patient adherence benefits
Orally Disintegrating	Superdisintegrants, flavoring agents	Growing niche market, especially for elderly or pediatric use

Conclusions

CARTIA’s excipient strategy focuses on stability, bioavailability, and regulatory compliance, with opportunities to develop differentiated formulations. Customizing excipients aligns with market trends toward controlled-release products, patient-centric formulations, and manufacturing efficiencies.

Key Takeaways

• Excipient selection for CARTIA targets stability, compatibility, and release profile control.
• Innovation in excipient combinations and formulations can unlock premium markets.
• Supply chain stability and regulatory adherence influence formulation success.
• Developing controlled-release or specialized formulations offers growth pathways.
• Patent protections on excipient innovation can extend market exclusivity.

FAQs

1. What is the primary role of excipients in CARTIA formulations?
   To facilitate manufacturing, stabilize the API, control drug release, and improve patient compliance.

2. Can excipient changes affect CARTIA’s efficacy?
   Yes. Changes can alter bioavailability or stability unless carefully validated.

3. Are there fillers or binders specific to controlled-release formulations?
   Yes. Hydrophilic polymers like HPMC are common in controlled-release matrices.

4. What are common regulatory concerns regarding excipients?
   Compatibility with API, purity, allergenicity, and comprehensive testing per pharmacopeial standards.

5. How can excipient innovation impact CARTIA’s market positioning?
   It allows formulation differentiation, patent opportunities, and tailored patient products, supporting premium pricing.

---

References

[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients.
[2] European Medicines Agency. (2021). Guideline on Pharmaceutical Development of Medicines for Human Use.
[3] USP-NF. (2022). United States Pharmacopeia–National Formulary.